SYN Share Price

Open 0.80 Change Price %
High 0.83 1 Day 0.00 0.00
Low 0.78 1 Week 0.02 2.53
Close 0.81 1 Month -0.68 -45.64
Volume 816127 1 Year -1.73 -68.11
52 Week High 2.73
52 Week Low 0.74
SYN Important Levels
Resistance 2 0.86
Resistance 1 0.84
Pivot 0.81
Support 1 0.78
Support 2 0.76
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
RBY 0.03 -70.00%
NAK 1.91 25.66%
NAK 1.91 25.66%
CVM 0.12 0.00%
CVM 0.12 0.00%
TPLM 0.40 11.11%
PBTH 8.23 0.37%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
NAK 1.91 25.66%
NAK 1.91 25.66%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
INV 0.14 -17.65%
More..

Synthetic Biologics, Inc (AMEX: SYN)

SYN Technical Analysis 5
As on 8th Dec 2016 SYN Share Price closed @ 0.81 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.74 & Strong Sell for SHORT-TERM with Stoploss of 1.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
SYN Target for December
1st Target up-side 1.25
2nd Target up-side 1.57
3rd Target up-side 1.89
1st Target down-side 0.35
2nd Target down-side 0.03
3rd Target down-side -0.29
SYN Other Details
Segment EQ
Market Capital 85700304.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.syntheticbiologics.com
SYN Address
SYN
155 Gibbs Street
Suite 412
Rockville, MD 20850
United States
Phone: 734-332-7800
Fax: 734-332-7878
SYN Latest News
Interactive Technical Analysis Chart Synthetic Biologics, Inc ( SYN AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Synthetic Biologics, Inc
SYN Business Profile
Synthetics Biologics, Inc., a biotechnology company, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases. The company’s product candidates include Trimesta, which has completed phase II clinical trials for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-010 that is in preclinical stage for the treatment of constipation-predominant irritable bowel syndrome; SYN-004, which is in preclinical stage for the treatment of clostridium difficile infection prevention; SYN-005 that is in preclinical stage for the treatment of pertussis; SYN-001, which is in discovery stage for the treatment of acinetobacter infection; and SYN-007 that is in discovery stage for the treatment of irritable bowel syndrome. It has a sublicense agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and Japan. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetics Biologics, Inc. in February 2012. Synthetics Biologics, Inc. was founded in 2001 and is based in Rockville, Maryland.